Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Retinal de novo lipogenesis coordinates neurotrophic signaling to maintain vision
Rithwick Rajagopal, … , Fong-Fu Hsu, Clay F. Semenkovich
Rithwick Rajagopal, … , Fong-Fu Hsu, Clay F. Semenkovich
Published January 11, 2018
Citation Information: JCI Insight. 2018;3(1):e97076. https://doi.org/10.1172/jci.insight.97076.
View: Text | PDF
Research Article Metabolism Ophthalmology

Retinal de novo lipogenesis coordinates neurotrophic signaling to maintain vision

  • Text
  • PDF
Abstract

Membrane lipid composition is central to the highly specialized functions of neurological tissues. In the retina, abnormal lipid metabolism causes severe forms of blindness, often through poorly understood neuronal cell death. Here, we demonstrate that deleting the de novo lipogenic enzyme fatty acid synthase (FAS) from the neural retina, but not the vascular retina, results in progressive neurodegeneration and blindness with a temporal pattern resembling rodent models of retinitis pigmentosa. Blindness was not rescued by protection from light-evoked activity; by eating a diet enriched in palmitate, the product of the FAS reaction; or by treatment with the PPARα agonist fenofibrate. Vision loss was due to aberrant synaptic structure, blunted responsiveness to glial-derived neurotrophic factor and ciliary neurotrophic factor, and eventual apoptotic cell loss. This progressive neurodegeneration was associated with decreased membrane cholesterol content, as well as loss of discrete n-3 polyunsaturated fatty acid– and saturated fatty acid–containing phospholipid species within specialized membrane microdomains. Neurotrophic signaling was restored by exogenous cholesterol delivery. These findings implicate de novo lipogenesis in neurotrophin-dependent cell survival by maintaining retinal membrane configuration and lipid composition, and they suggest that ongoing lipogenesis may be required to prevent cell death in many forms of retinopathy.

Authors

Rithwick Rajagopal, Sheng Zhang, Xiaochao Wei, Teresa Doggett, Sangeeta Adak, Jennifer Enright, Vaishali Shah, Guoyu Ling, Shiming Chen, Jun Yoshino, Fong-Fu Hsu, Clay F. Semenkovich

×

Figure 5

Synaptic ultrastructure in retinal FAS mutants.

Options: View larger image (or click on image) Download as PowerPoint
Synaptic ultrastructure in retinal FAS mutants.
(A) Transmission electro...
(A) Transmission electron microscopy showing control rod (asterisks) and cone (arrowhead) nuclear morphology and lamination at P28. (B) FASKO rod (asterisks) and cone (arrowhead) nuclear morphology and lamination at P28. (C) FASKO rod (asterisks) and cone (light arrowheads) nuclei at P60 around a pseudorosette with the external limiting membrane remaining intact (dark arrowheads). (D) Typical ribbon synapse at a rod spherule in control retina with intact ribbon strut (asterisk) and densely packed surrounding glutamatergic vesicles. (E) Decreased vesicular density around ribbon strut in FASKO rod spherules (asterisk) at P28. (F) Decreased vesicular density around ribbon strut in FASKO cone pedicles (asterisk) at P28. Clathrin-coated vesicles are indicated by arrowheads. Representative images from each panel with n = 2 for control tissues and n = 5 for FASKO tissues.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts